PAREXEL EXPERTS TO PRESENT INSIGHTS INTO SUCCESSFUL GLOBAL PRODUCT DEVELOPMENT STRATEGIES AT “FROM ASIA TO THE WORLD” SEMINAR

Boston, MA, July 14, 2010 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that experts from the Company will deliver several presentations and lead panel discussions at the “From Asia to the World—Global Integration of Clinical Research” seminar, to be held July 15 - 16 at the Taipei International Convention Center in Taiwan. The seminar, which PAREXEL has organized with National Taiwan University Hospital (NTUH) and Taiwan Association of Institutional Review Boards (TAIRB), will provide insights into key strategies to execute successful product development plans for biopharmaceutical markets worldwide. The seminar’s opening remarks will be delivered by Dr. Jaw-Jou Kang, Director General, Taiwan Food and Drug Administration, Department of Health.

Bringing together globally- and regionally-based biopharmaceutical companies, clinical site investigators, and government leaders, as well as representatives from regional regulatory authorities and academia, the seminar’s goal is to encourage more in-depth collaboration and global clinical research participation among various biopharmaceutical industry stakeholders in Taiwan and throughout Asia. The seminar is designed to help attendees learn about innovative trial design approaches and optimal regulatory and clinical pathways for drug development in established and emerging biopharmaceutical markets. Additionally, attendees will gain an understanding of how to utilize integrated eClinical solutions to bring more efficiency to the trial process.

In addition to presenting welcome remarks, Albert Liou, Corporate Vice President and General Manager, Asia/Pacific Region, PAREXEL, will serve as moderator of a panel session that will summarize discussions from the first day of the seminar. Alberto Grignolo, Ph.D., Corporate Vice President, Global Strategy, PAREXEL Consulting, will present “Global Drug Development Today—Past Present, and Future of Simultaneous Drug Development” and also moderate a final panel discussion to close the seminar.

Other PAREXEL experts will lead the following sessions during the seminar:

• “Early Phase Drug Development—Rapid Path to Proof of Concept,” Stanford Jhee, Pharm. D., Senior Director, Early Phase, PAREXEL
• “Global eClinical Development and Implementation,” George Hunnewell, Vice President, Perceptive Informatics
• “Global Outsourcing Trends Today: Insourcing or Outsourcing?—Cost Efficient Ways of Conducting Clinical Trials,” Karen Chu, Vice President, Project Management, PAREXEL
• “Experience Sharing on FDA Inspections,” Vicki Liao, Director, On-Site Monitoring, PAREXEL

For more information about PAREXEL’s capabilities to assist biopharmaceutical companies worldwide with product development in established and emerging markets visit: http://www.parexel.com/services-and-capabilities. More information about this seminar can be found at: http://www.crintegration.com/about.html.

                                                           # # #

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.